Current Headlines

  1. New Therapeutic Target May Help Improve Cancer Drugs’ Efficacy
    8/1/2014
    Researchers from the Barts Cancer Institute, associated with Queen Mary University of London, reported that targeting the molecule focal adhesion kinase (FAK) may help enhance the efficacy of cancer drugs.
  2. Wyss Announces Commercialization Arrangement For Organs-On-Chips Technology
    8/1/2014
    The Wyss Institute for Biologically Inspired Engineering at Harvard University declared that its Organs-on-Chips technology will be marketed by a newly formed private firm, Emulate. The new company aims to speed development of the technology in pharmaceuticals, cosmetic, chemicals, and personalized medicine applications.
  3. Lion Biotech Funds Moffit Cancer Trial Expansion
    8/1/2014
    Lion Biotech has signed into a clinical trial grant agreement with Moffitt Cancer Center to fund the expansion of an ongoing Phase I cancer study of Lion’s tumor infiltrating lymphocytes (TILs) in combination with Bristol-Myers Squibb’s ipilimumab in patients with metastatic melanoma.
  4. AstraZeneca, Kyowa-Hakko-Kirin To Collaborate In Immuno-Oncology Study
    8/1/2014

    AstraZeneca announced that they will co-fund a study to be conducted by Kyowa Hakko Kirin that will test two separate combinations of three experimental compounds in the hopes of developing safe and effective immuno-oncology treatments.

  5. Auckland Researchers Use Zebrafish To Screen Cancer Drugs
    7/31/2014
    A new study from the University of Auckland reports that zebrafish embryos helped researchers screen thousands of compounds to identify four new potential anti-cancer drugs.
  6. Artes And Burnet Partner In New Malaria Vaccine
    7/31/2014
    Artes Biotech and Burnet Institute have entered into collaboration to work on a new kind of malaria vaccine.
  7. NIH Awards $49M Grant To SRI For HIV/AIDS Drug Development
    7/31/2014
    SRI Biosciences announced in a press release that the National Institutes of Health (NIH) has awarded the company a seven-year grant of $49 million for HIV/AIDS drug development. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is administering the grant for preclinical development of potential therapies, including the infections prevalent in the disease. The grant also funds research for microbicides to prevent the sexual transmission of HIV.
  8. Cellectis Sells Swedish Subsidiary Cellectis AB To Takara Bio
    7/31/2014
    Cellectis announced in a press release that it has sold its Swedish subsidiary Cellectis AB to Takara Bio, a Japanese company. The sale, to be finalized soon, allows Cellectis to refocus on oncology therapies and its Chimeric Antigen Receptor T-cell (CART) immunotherapy products. Cellectis is currently partnered with Servier, Pfizer, and Accelera, a contract research organization (CRO), on CART technology. Cellectis also recently announced an agreement with European CELLforCURE to manufacture clinical batches of Cellectis’ CART cells. The sale is part of Cellectis’ restructuring effort.
  9. Otsuka, Horizon CombinatoRx Sign $835K In Vitro Cell Line Screening Deal
    7/31/2014

    Otsuka Pharmaceutical Development and Commercialization (OPDC) has inked a $846 thousand deal with Horizon CombinatoRx, a division of the UK-based business Horizon Discovery, to perform in vitro cell line screening of certain OPDC drug development candidates in 2014.

  10. Harlan Provides Expertise For Biologics And Biosimilars
    7/31/2014

    Harlan Laboratories, Ltd., a privately held provider of general and specialty toxicology services through its Contract Research Services (CRS) business, is prepared to meet the global demand for development programs in novel biologics and biosimilars.

Newsletter Signup
Newsletter Signup